Joseph Michael Fitzgerald - Feb 21, 2023 Form 4 Insider Report for BOSTON SCIENTIFIC CORP (BSX)

Role
EVP & Group Pres, Cardiology
Signature
/s/ Susan Thompson, Attorney-in-Fact
Stock symbol
BSX
Transactions as of
Feb 21, 2023
Transactions value $
-$88,900
Form type
4
Date filed
2/22/2023, 03:54 PM
Previous filing
Feb 21, 2023
Next filing
May 17, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BSX Common Stock Options Exercise $0 +3.9K +1.78% $0.00 222K Feb 21, 2023 Direct F1
transaction BSX Common Stock Tax liability -$88.9K -1.92K -0.87% $46.23 220K Feb 21, 2023 Direct
holding BSX Common Stock 68.1K Feb 21, 2023 By 401(k) F2
holding BSX Common Stock 4.34K Feb 21, 2023 By Child F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BSX Deferred Stock Units Options Exercise $0 -3.9K -100% $0.00* 0 Feb 21, 2023 Common Stock 3.9K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
F2 Balance reflects the most current data available with regard to share holdings in the Company's 401(k) Retirement Savings Plan.
F3 The reporting person disclaims beneficial ownership of the shares held by his child, and this report should not be deemed an admission that the reporting person is the beneficial owner of his child's shares for purposes of Section 16 or for any other purpose.
F4 Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant.